Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 11/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1597169 | 1.00 | GAA (0.39) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596497 | 1.00 | GAA (0.39) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596838 | 0.92 | GAA (0.38) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596835 | 0.92 | GAA (0.38) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596841 | 0.92 | GAA (0.38) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596024 | 0.91 | GAA (0.40) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1596022 | 0.91 | GAA (0.40) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1595945 | 0.91 | GAA (0.41) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1595940 | 0.91 | GAA (0.41) | GAASYKTAS2R14PRMT5WDR77 | |
| SCHEMBL1595946 | 0.91 | GAA (0.41) | GAASYKTAS2R14PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | claimed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | claimed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1509218-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1509218-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | MRPL21, NRDC, SPOUT1 | GAA 541/4885SYK 4149/4885TAS2R14 2645/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | GAA 1043/4885SYK 4390/4885TAS2R14 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.